Achieve Life Sciences Draws an FDA Complete Response Letter on Cytisinicline

Achieve Life Sciences hit a regulatory wall this week, but the setback looks more like a delay than a dead end.

The Nasdaq-listed micro-cap is built around a single asset: cytisinicline, a plant-derived treatment for nicotine dependence that could become the first new prescription smoking-cessation medicine in roughly two decades. Its application was supported by two completed Phase 3 trials and a large open-label safety program.

On June 22 the FDA issued a complete response letter for the cytisinicline new drug application. Crucially, the agency flagged no problems with the drug's clinical efficacy or safety; the letter cited outstanding manufacturing observations from a third-party facility inspection and product labeling that was not finalized by the action date. Achieve said it plans to resubmit in the fourth quarter of 2026, naming Adare as its primary manufacturing partner, with potential approval in the first half of 2027. Its safety database includes more than 400 participants dosed for at least six months.

Manufacturing-related rejections can still slip, and a cash-strapped micro-cap may need to raise money before any relaunch.

This is market commentary, not investment advice — small-cap biotech stocks are highly speculative and you can lose your entire investment.